Incretin accelerates platelet-derived growth factor-BB-induced osteoblast migration via protein kinase A: The upregulation of p38 MAP kinase.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
11 02 2020
11 02 2020
Historique:
received:
12
07
2018
accepted:
27
01
2020
entrez:
13
2
2020
pubmed:
13
2
2020
medline:
13
3
2021
Statut:
epublish
Résumé
Incretins, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), secreted from enteroendocrine cells after food ingestion, are currently recognized to regulate glucose metabolism through insulin secretion. We previously demonstrated that platelet-derived growth factor-BB (PDGF-BB) induces the migration of osteoblast-like MC3T3-E1 cells through mitogen-activated protein (MAP) kinases, including p38 MAP kinase. In the present study, we investigated whether or not incretins affect the osteoblast migration. The PDGF-BB-induced cell migration was significantly reinforced by GLP-1, GIP or cAMP analogues in MC3T3-E1 cells and normal human osteoblasts. The upregulated migration by GLP-1 or cAMP analogues was suppressed by H89, an inhibitor of protein kinase A. The amplification by GLP-1 of migration induced by PDGF-BB was almost completely reduced by SB203580, a p38 MAP kinase inhibitor in MC3T3-E1 cells and normal human osteoblasts. In addition, GIP markedly strengthened the PDGF-BB-induced phosphorylation of p38 MAP kinase. Exendin-4, a GLP-1 analogue, induced Rho A expression and its translocation from cytoplasm to plasma membranes in osteoblasts at the epiphyseal lines of developing mouse femurs in vivo. These results strongly suggest that incretins accelerates the PDGF-BB-induced migration of osteoblasts via protein kinase A, and the up-regulation of p38 MAP kinase is involved in this acceleration. Our findings may highlight the novel potential of incretins to bone physiology and therapeutic strategy against bone repair.
Identifiants
pubmed: 32047216
doi: 10.1038/s41598-020-59392-7
pii: 10.1038/s41598-020-59392-7
pmc: PMC7012849
doi:
Substances chimiques
Incretins
0
Becaplermin
1B56C968OA
Cyclic AMP-Dependent Protein Kinases
EC 2.7.11.11
p38 Mitogen-Activated Protein Kinases
EC 2.7.11.24
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2341Références
Karsenty, G. & Wagner, E. F. Reaching a genetic and molecular understanding of skeletal development. Dev. Cell 2, 389–406 (2002).
doi: 10.1016/S1534-5807(02)00157-0
Kular, J., Tickner, J., Chim, S. M. & Xu, J. An overview of the regulation of bone remodeling at the cellular level. Clin. Biochem. 45, 863–873 (2012).
doi: 10.1016/j.clinbiochem.2012.03.021
Khan, S. N., Bostrom, M. P. & Lane, J. M. Bone growth factors. Orthop. Clin. North. Am. 31, 375–388 (2000).
doi: 10.1016/S0030-5898(05)70157-7
Lieberman, J. R., Daluiski, A. & Einhorn, T. A. The role of growth factors in the repair of bone. Biology and clinical applications. J. Bone Jt. Surg. Am. 84-A, 1032–1044 (2002).
doi: 10.2106/00004623-200206000-00022
Reddi, A. H., Roodman, D., Freeman, C. & Mohla, S. Mechanisms of tumor metastasis to the bone: Challenges and opportunities. J. Bone Min. Res. 18, 190–194 (2003).
doi: 10.1359/jbmr.2003.18.2.190
Heldin, C. H. & Westermark, B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol. Rev. 79, 1283–1316 (1999).
doi: 10.1152/physrev.1999.79.4.1283
Canalis, E. Growth factor control of bone mass. J. Cell Biochem. 108, 769–777 (2009).
doi: 10.1002/jcb.22322
Caplan, A. I. & Correa, D. PDGF in bone formation and regeneration: new insights into a novel mechanism involving MSCs. J. Ortho Res. 29, 1795–1803 (2011).
doi: 10.1002/jor.21462
Hollinger, J. O., Hart, C. E., Hirsch, S. N., Lynch, S. & Friedlaender, G. E. Recombinant human platelet-derived growth factor: biology and clinical applications. J. Bone Jt. Surg. Am. 90(Suppl 1), 48–54 (2008).
doi: 10.2106/JBJS.G.01231
Hengartner, N. E., Fiedler, J., Ignatius, A. & Brenner, R. E. IL-1β inhibits human osteoblast migration. Mol. Med. 19, 36–42 (2013).
doi: 10.2119/molmed.2012.00058
Takai, S., Tokuda, H., Hanai, Y. & Kozawa, O. Limitation by p70 S6 kinase of platelet-derived growth factor-BB-induced interleukin 6 synthesis in osteoblast-like MC3T3-E1 cells. Metab. 56, 476–483 (2007).
doi: 10.1016/j.metabol.2006.11.005
Kainuma, S. et al. Heat shock protein 27 (HSPB1) suppresses PDGF-BB-induced migration of osteoblasts. Int. J. Mol. Med. 40, 1057–1066 (2017).
doi: 10.3892/ijmm.2017.3119
Holst, J. J. The physiology of glucagon-like peptide 1. Physiol. Rev. 87, 1409–1439 (2007).
doi: 10.1152/physrev.00034.2006
Meier, C., Schwartz, A. V., Egger, A. & Lecka-Czernik, B. Effects of diabetes drugs on the skeleton. Bone 82, 93–100 (2016).
doi: 10.1016/j.bone.2015.04.026
Baggio, L. L. & Drucker, D. J. Biology of incretins: GLP-1 and GIP. Gastroenterology 132, 2131–2157 (2007).
doi: 10.1053/j.gastro.2007.03.054
Luo, G., Liu, H. & Lu, H. Glucagon-like peptide-1 (GLP-1) receptor agonists: potential to reduce fracture risk in diabetic patients? Br. J. Clin. Pharmacol. 81, 78–88 (2016).
doi: 10.1111/bcp.12777
Bollag, R. J. et al. Glucose-dependent insulinotropic peptide is an integrative hormone with osteotropic effects. Mol. Cell Endocrinol. 177, 35–41 (2001).
doi: 10.1016/S0303-7207(01)00405-1
Yamada, C. et al. The murine gluzagon-like paptide-1 receptor is essential for control of bone resorption. Endcrinology 149, 574–579 (2008).
doi: 10.1210/en.2007-1292
Bollag, R. J. et al. Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors. Endcrinology 141, 1228–1235 (2000).
doi: 10.1210/endo.141.3.7366
Sanz, C. et al. Signaling and biological effects of glucagon-like peptide 1 on the differentiation of mesenchymal stem cells from human bone marrow. Am. J. Physiol. Endocrinol. Metab. 298, E634–E643 (2010).
doi: 10.1152/ajpendo.00460.2009
Kaibuchi, K., Kuroda, S. & Amano, M. Regulation of the cytoskeleton and cell adhesion by the Rho family GTPases in mammalian cells. Annu. Rev. Biochem. 68, 459–486 (1999).
doi: 10.1146/annurev.biochem.68.1.459
Kawabata, T. et al. Repression of IGF-I-induced osteoblast migration by (−)-epigallocatechin gallate through p44/p42 MAP kinase signaling. Biomed. Rep. 9, 318–326 (2018).
pubmed: 30233784
pmcid: 6142041
Sudo, H., Kodama, H., Amagai, Y., Yamamoto, S. & Kasai, S. In vitro differentiation and calcification in a new clonal osteogenic cell line derived from newborn mouse calvaria. J. Cell Biol. 96, 191–198 (1983).
doi: 10.1083/jcb.96.1.191
Kozawa, O., Tokuda, H., Miwa, M., Kotoyori, J. & Oiso, Y. Cross-talk regulation between cyclic AMP production and phosphoinositide hydrolysis induced by prostaglandin E2 in osteoblast-like cells. Exp. Cell Res. 198, 130–134 (1992).
doi: 10.1016/0014-4827(92)90158-5
Kondo, A. et al. Inhibition of SAPK/JNK leads to enhanced IL-1-induced IL-6 synthesis in osteoblasts. Arch. Biochem. Biophys. 535, 227–233 (2013).
doi: 10.1016/j.abb.2013.04.007
Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nat. 227, 680–685 (1970).
doi: 10.1038/227680a0
Kato, K. et al. Modulation of the stress-induced synthesis of hsp27 and αB-crystallin by cyclic AMP in C6 rat glioma cells. J. Neurochem. 66, 946–950 (1996).
doi: 10.1046/j.1471-4159.1996.66030946.x
Thorens, B. et al. Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 42, 1678–1682 (1993).
doi: 10.2337/diab.42.11.1678
Yu, Z. & Jin, T. New insights into the role of cAMP in the production and function of the incretin hormone glucagon-like peptide-1 (GLP-1). Cell Signal. 22, 1–8 (2010).
doi: 10.1016/j.cellsig.2009.09.032
Fujita, K. et al. Incretins amplify TNF-α-stimulated IL-6 synthesis in osteoblasts: suppression of the IkB/NF-kB pathway. Int. J. Mol. Med. 39, 1053–1060 (2017).
doi: 10.3892/ijmm.2017.2892
Schwede, F., Maronde, E., Genieser, H. & Jastorff, B. Cyclic nucleotide analogs as biochemical tools and prospective drugs. Pharmacol. Ther. 87, 199–226 (2000).
doi: 10.1016/S0163-7258(00)00051-6
Chijiwa, T. et al. Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells. J. Biol. Chem. 265, 5267–5272 (1990).
pubmed: 2156866
Lessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T. & Saltiel, A. R. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J. Biol. Chem. 270, 27489–27494 (1995).
doi: 10.1074/jbc.270.46.27489
Bennett, B. L. et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl Acad. Sci. USA 98, 13681–13686 (2001).
doi: 10.1073/pnas.251194298
Cuenda, A. et al. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett. 364, 229–233 (1995).
doi: 10.1016/0014-5793(95)00357-F
Holst, J. J. The physiology of glucagon-like peptide 1. Physiol. Rev. 87, 1409–1439 (2007).
doi: 10.1152/physrev.00034.2006
Nuche-Berenguer, B. et al. Presence of a functional receptor for GLP-1 in osteoblastic cells, independent of the cAMP-linked GLP-1 receptor. J. Cell Physiol. 225, 585–592 (2010).
doi: 10.1002/jcp.22243
Seino, Y. & Yabe, D. Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas. J. Diabetes Investig. 4, 108–130 (2013).
doi: 10.1111/jdi.12065
Lochner, A. & Moolman, J. A. The many faces of H89: a review. Cardiovascular Drug. Reviews. 24, 261–274 (2006).
doi: 10.1111/j.1527-3466.2006.00261.x
Hamann, C., Kirschner, S., Günter, K. P. & Hofbouer, L. C. Bone, sweet bone-osteoporotic fractures in diabetes mellitus. Nat. Rev. Endocrinol. 8, 297–305 (2012).
doi: 10.1038/nrendo.2011.233